CD4 and non-small cell lung carcinoma: Although it is generally believed that high levels of NK, CD4+ T, and CD8+ T cells predict better tumor response and prolonged PFS in patients with NSCLC (23, 24), the findings of one study have indicated that high baseline NK cell levels in patients with advanced NSCLC treated with nivolumab are associated with a poor prognosis (14).